Hologic, Inc. (HOLX)
Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 18.005
- Book/Share 21.5879
- PB 3.1115
- Debt/Equity 0.5209
- CurrentRatio 3.5547
- ROIC 0.0743
- MktCap 14939884230.0
- FreeCF/Share 4.3608
- PFCF 15.2728
- PE 27.0458
- Debt/Assets 0.2864
- DivYield 0
- ROE 0.1151
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HOLX | Argus | Hold | Buy | -- | $80 | Aug. 18, 2025 |
| Upgrade | HOLX | RBC Capital Mkts | Sector Perform | Outperform | -- | $87 | Aug. 6, 2025 |
| Upgrade | HOLX | Citigroup | Neutral | Buy | -- | $80 | July 9, 2025 |
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Reiterated | HOLX | Needham | -- | Buy | -- | $90 | Dec. 10, 2024 |
| Initiation | HOLX | Jefferies | -- | Hold | -- | $85 | Dec. 10, 2024 |
News
Here's Why Hologic (HOLX) is a Strong Value Stock
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Read More
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
Read More
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Read More
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Interpreting Hologic (HOLX) International Revenue Trends
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Read More
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Read More
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Read More
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
Read More
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
Read More
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Read More
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Read More
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Read More
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hologic Climbs 13% in a Month: How Should You Play the Stock?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively.
Read More
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
Read More
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.
Read More
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
Published: May 27, 2025 by: Proactive Investors
Sentiment: Neutral
TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a media report from the Financial Times. Citing people with knowledge of the matter, the publication said Massachusetts-based Hologic has rejected the offer.
Read More
Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports
Published: May 27, 2025 by: Reuters
Sentiment: Negative
Medical equipment maker Hologic rejected a $16 billion non-binding offer from private equity firms TPG and Blackstone , the Financial Times reported on Tuesday, citing people familiar with the matter.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen P. MacMillan
- Employees 7063